相关实验视频
Updated: May 23, 2025
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.2K
卡比多巴:除了帕金森病之外
Abhishek Lenka1, Steven Vernino2
1Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA. abhishek.lenka@utsouthwestern.edu.
概括
卡比多巴除了帕金森病之外,还显示出对家族性dysautonomia和POTS等自主性障碍的承诺. 它有效地管理恶心和同情性多动症,具有良好的安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
- 内部医学 内部医学
背景情况:
- 卡比多巴主要以其在帕金森病管理中的作用而闻名.
- 自主性疾病在患者护理中带来了复杂的挑战.
- 了解新的治疗应用对于改善患者的治疗结果至关重要.
研究的目的:
- 审查carbidopa的药理学和现实世界的应用.
- 探索卡比多巴在管理帕金森病以外的自主性疾病中的实用性.
主要方法:
- 在PubMed.com上进行了全面的文献搜索.
- 使用的关键词包括"Carbidopa"",MK-486"和"L-alpha-methyldopa hydrazine.
- 文章被选中在2025年1月进行审查.
主要成果:
- 卡比多巴在治疗家族性失调症,高上腺性POTS和 afferent baroreflex失效中的恶心和交感性过活性的治疗中表现出有效性.
- 高剂量 (高达600毫克/天) 在家族性dysautonomia的临床试验中通常耐受良好.
- 临床前数据表明,carbidopa可能抑制T细胞激活,并有可能导致细胞因子释放综合征.
结论:
- 卡比多巴在自主障碍管理方面表现出良好的安全性.
- 有限的证据表明,卡比多巴在治疗恶心和同情性多动症症状方面具有实用性.
- 需要进一步的大规模研究来证实carbidopa在这些疾病中的治疗作用.
相关概念视频
01:24Parkinson's Disease: Treatment
178
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
178
01:15Parkinson's Disease: Overview
415
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
415
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
663
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
663
01:26Cholinergic Antagonists: Therapeutic Uses
699
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
699
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
232
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
232
01:22Alzheimer's Disease: Treatment
142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142